| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 7587.0 | 6864.5 | 6527.9 |
| Other income | 134.2 | 111.4 | 80.6 |
| Total income | 7721.2 | 6975.9 | 6608.5 |
| Profit before exceptional items & tax | 2057.2 | 1438.3 | 1891.6 |
| Exceptional items | 397.5 | 84.9 | 219.6 |
| Profit before tax | 1659.7 | 1353.4 | 1672.0 |
| Net profit | 1272.5 | 1042.1 | 1170.9 |
| Operating margin | 21.5% | 19.4% | 25.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +8.70% |
|---|---|
| Net profit, quarter on quarter | +22.10% |
| Revenue, year on year | +16.20% |
BSE results filing, NSE: ZYDUSLIFE. Figures extracted from the filing.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,203.90
- Market cap
- ₹1,21,141 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 26.8×Sector 50.4×
- Promoter holding
- 75.01%+0.01% QoQ
- FII holding
- 6.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Business Update
Zydus Lifesciences announced that a recent USFDA inspection of its pharmacovigilance and post-marketing surveillance system at the company’s USA office concluded with nil observations.
Zydus Lifesciences Credit Rating
CRISIL reaffirmed Zydus Lifesciences ratings: CRISIL AAA/Stable (LT) and A1+ (ST) on a Rs.4,724 Cr bank facility, plus CPs and NCDs. The stable outlook signals unchanged strong credit standing.
Zydus Lifesciences Legal & Regulatory
Zydus Lifesciences' subsidiary, ZPUI, settled an antitrust litigation case for a total payment of USD 5.9 million, without admission of wrongdoing.
- Value
- ₹55.46 Cr
Zydus Lifesciences Earnings Call Transcript: Key Takeaways
Zydus delivered robust FY27 Q1 results driven by strong India-branded formulations and U.S. generic resilience.
- Call
- Guides 10% growth
Zydus Lifesciences Investor Presentation: Key Takeaways
Zydus Lifesciences reported strong Q1 FY27 revenue growth of 22% YoY, driven by robust performance in India and International formulations, despite a decline in PAT and EBITDA margins.
Zydus Lifesciences Q1 FY27 Results: Net Profit ₹939.8 Cr, Down 35.9% YoY
Zydus Lifesciences Ltd reported revenue from operations of ₹8,017 Cr (+22.0% YoY) and net profit of ₹939.8 Cr (-35.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹939.8 Cr · -35.9% YoY